Role of bile acids in inflammatory bowel disease

Annals of Gastroenterology

Volumn 31, Issue 3, 2018, Pages 266-272

  Tiratterra, Elisa ^a   Franco, Placido ^c   Porru, Emanuele ^c   Katsanos, Konstantinos H ^b   Christodoulou, Dimitrios K ^b   Roda, Giulia ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF IOANNINA   (Greece)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Bile acids; Crohn s disease; Farnesoid X receptor; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

BILE ACID; FARNESOID X RECEPTOR; FIBROBLAST GROWTH FACTOR 19;

BILE ACID METABOLISM; CONJUGATION; CROHN DISEASE; DIARRHEA; HUMAN; INFLAMMATORY BOWEL DISEASE; MALABSORPTION; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; ULCERATIVE COLITIS;

EID: 85046437053     PISSN: 11087471     EISSN: 17927463     Source Type: Journal    
DOI: 10.20524/aog.2018.0239     Document Type: Review

References (54)

1. Gadaleta RM, van Mil SW, Oldenburg B, Siersema PD, Klomp LW, van Erpecum KJ. Bile acids and their nuclear receptor FXR: Relevance for hepatobiliary and gastrointestinal disease. Biochim Biophys Acta 2010;1801:683-692.
2. Parks DJ, Blanchard SG, Bledsoe RK, et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 1999;284:1365-1368.
3. Vítek L. Bile acid malabsorption in inflammatory bowel disease. Inflamm Bowel Dis 2015;21:476-483.
4. Philipp B. Bacterial degradation of bile salts. Appl Microbiol Biotechnol 2011;89:903-915.
5. Ejderhamn J, Strandvik B. Serum bile acids in relation to disease activity and intake of dietary fibers in juvenile ulcerative colitis. Digestion 1991;50:162-169.
6. Kostić N, Bozanić M, Cvetković R, Adamov A. [Lipids and total bile acids in the blood of patients with inflammatory bowel diseases]. Srp Arh Celok Lek 1990;118:43-46.
7. Goodwin B, Jones SA, Price RR, et al. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell 2000;6:517-526.
8. Roda A, Pellicciari R, Gioiello A, et al. Semisynthetic bile acid FXR and TGR5 agonists: physicochemical properties, pharmacokinetics, and metabolism. J Pharmacol Exper Ther 2014;350:56-68.
9. Roda A, Aldini R, Camborata C, et al. Metabolic profile of obeticholic acid and endogenous bile acids in rats with decompensated liver cirrhosis. Clin Transl Sci 2017;10:292-301.
10. Agellon LB, Torchia EC. Intracellular transport of bile acids. Biochim Biophys Acta 2000;1486:198-209.
11. Hofmann AF, Hagey LR. Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics. Cell Molec Life Sci 2008;65:2461-2483.
12. Chiang JY. Bile acids: regulation of synthesis. J Lipid Res 2009;50:1955-1966.
13. Russell DW. Fifty years of advances in bile acid synthesis and metabolism. J Lipid Res 2009;50 (Suppl): S120-S125.
14. Makishima M, Okamoto AY, Repa JJ, et al. Identification of a nuclear receptor for bile acids. Science 1999;284:1362-1365.
15. Wang H, Chen J, Hollister K, Sowers LC, Forman BM. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell 1999,3:543-553.
16. Zhang Y, Edwards PA. FXR signaling in metabolic disease. FEBS Lett 2008;582:10-18.
17. Li Y, Jadhav K, Zhang Y. Bile acid receptors in non-alcoholic fatty liver disease. Biochem Pharmacol 2013;86:1517-1524.
18. Huber RM, Murphy K, Miao B, et al. Generation of multiple farnesoid-X-receptor isoforms through the use of alternative promoters. Gene 2002;290:35-43.
19. Chen F, Ma L, Dawson PA, et al. Liver receptor homologue-1 mediates species- and cell line-specific bile acid-dependent negative feedback regulation of the apical sodium-dependent bile acid transporter. J Biol Chem 2003;278:19909-19916.
20. Grober J, Zaghini I, Fujii H, et al. Identification of a bile acid-responsive element in the human ileal bile acid-binding protein gene. Involvement of the farnesoid X receptor/9-cis-retinoic acid receptor heterodimer. J Biol Chem 1999;274:29749-29754.
21. Lee H, Zhang Y, Lee FY, Nelson SF, Gonzalez FJ, Edwards PA. FXR regulates organic solute transporters alpha and beta in the adrenal gland, kidney, and intestine. J Lipid Res 2006;47:201-214.
22. Holt JA, Luo G, Billin AN, et al. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev 2003;17:1581-1591.
23. Inagaki T, Choi M, Moschetta A, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005;2:217-225.
24. Xie MH, Holcomb I, Deuel B, et al. FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4. Cytokine 1999;11:729-735.
25. Fiorucci S, Cipriani S, Mencarelli A, Renga B, Distrutti E, Baldelli F. Counter-regulatory role of bile acid activated receptors in immunity and inflammation. Curr Mol Med 2010;10:579-595.
26. Kong B, Wang L, Chiang JY, Zhang Y, Klaassen CD, Guo GL. Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice. Hepatology 2012;56:1034-1043.
27. Wagner EF, Eferl R. Fos/AP-1 proteins in bone and the immune system. Immunol Rev 2005;208:126-140.
28. Ding L, Yang L, Wang Z, Huang W. Bile acid nuclear receptor FXR and digestive system diseases. Acta Pharm Sin B 2015;5:135-144.
29. Gadaleta RM, van Erpecum KJ, Oldenburg B, et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut 2011;60:463-472.
30. Gadaleta RM, Oldenburg B, Willemsen EC, et al. Activation of bile salt nuclear receptor FXR is repressed by pro-inflammatory cytokines activating NF-κB signaling in the intestine. Biochim Biophys Acta 2011;1812:851-858.
31. Jahnel J, Fickert P, Hauer AC, Högenauer C, Avian A, Trauner M. Inflammatory bowel disease alters intestinal bile acid transporter expression. Drug Metab Dispos 2014;42:1423-1431.
32. Nijmeijer RM, Gadaleta RM, van Mil SW, et al. Farnesoid X receptor (FXR) activation and FXR genetic variation in inflammatory bowel disease. PLoS One 2011;6:e23745.
33. Camilleri M. Bile acid diarrhea: prevalence, pathogenesis, and therapy. Gut Liver 2015;9:332-339.
34. Aldini R, Roda A, Festi D, et al. Diagnostic value of serum primary bile acids in detecting bile acid malabsorption. Gut 1982;23:829-834.
35. Fromm H, Hofmann AF. Breath test for altered bile-acid metabolism. Lancet 1971;2:621-625.
36. Williams AJ, Merrick MV, Eastwood MA. Idiopathic bile acid malabsorption—a review of clinical presentation, diagnosis, and response to treatment. Gut 1991;32:1004-1006.
37. Camilleri M, Nadeau A, Tremaine WJ, et al. Measurement of serum 7alpha-hydroxy-4-cholesten-3-one (or 7alphaC4), a surrogate test for bile acid malabsorption in health, ileal disease and irritable bowel syndrome using liquid chromatography-tandem mass spectrometry. Neurogastroenterol Motil 2009;21:734-e43.
38. Camilleri M, Busciglio I, Acosta A, et al. Effect of increased bile acid synthesis or faecal excretion in irritable bowel syndrome-diarrhea. Am J Gastroenterol 2014;109:1621-1630.
39. Walters JR, Pattni SS. Managing bile acid diarrhoea. Therap Adv Gastroenterol 2010;3:349-357.
40. Covington JA, Westenbrink EW, Ouaret N, et al. Application of a novel tool for diagnosing bile acid diarrhoea. Sensors (Basel) 2013;13:11899-11912.
41. Fromm H, Malavolti M. Bile acid-induced diarrhea. Clin Gastroenterolol 1986;15:567-582.
42. Hofmann AF, Poley JR. Role of bile acid malabsorption in pathogenesis of diarrhea and steatorrhea in patients with ileal resection. I. Response to cholestyramine or replacement of dietary long chain triglyceride by medium chain triglyceride. Gastroenterology 1972;62:918-934.
43. Alrefai WA, Gill RK. Bile acid transporters: structure, function, regulation and pathophysiological implications. Pharm Res 2007;24:1803-1823.
44. Hofmann AF. Chronic diarrhea caused by idiopathic bile acid malabsorption: an explanation at last. Exp Rev Gastroenterol Hepatol 2009;3:461-464.
45. Keely SJ, Walters JR. The farnesoid X receptor: good for BAD. Cell Mol Gastroenterol Hepatol 2016;2:725-732.
46. Lenicek M, Duricova D, Komarek V, et al. Bile acid malabsorption in inflammatory bowel disease: assessment by serum markers. Inflamm Bowel Dis 2011;17:1322-1327.
47. Miettinen TA. The role of bile salts in diarrhoea of patients with ulcerative colitis. Gut 1971;12:632-635.
48. Hakala K, Vuoristo M, Luukkonen P, Järvinen HJ, Miettinen TA. Impaired absorption of cholesterol and bile acids in patients with an ileoanal anastomosis. Gut 1997;41:771-777.
49. Gnewuch C, Liebisch G, Langmann T, et al. Serum bile acid profiling reflects enterohepatic detoxification state and intestinal barrier function in inflammatory bowel disease. World J Gastroenterol 2009;15:3134-3141.
50. Scaldaferri F, Pizzoferrato M, Ponziani FR, Gasbarrini G, Gasbarrini A. Use and indications of cholestyramine and bile acid sequestrants. Intern Emerg Med 2013;8:205-210.
51. Meihoff WE, Kern F Jr. Bile salt malabsorption in regional ileitis, ileal resection and mannitol-induced diarrhea. J Clin Invest 1968;47:261-267.
52. Mena Bares LM, Carmona Asenjo E, García Sánchez MV, et al. 75SeHCAT scan in bile acid malabsorption in chronic diarrhoea. Rev Esp Med Nucl Imagen Mol 2017;36:37-47.
53. Nolan JD, Johnston IM, Walters JR. Altered enterohepatic circulation of bile acids in Crohn’s disease and their clinical significance: a new perspective. Expert Rev Gastroenterol Hepatol 2013;7:49-56.
54. Duboc H, Rajca S, Rainteau D, et al. Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut 2013;62:531-539.